Drug Profile
Research programme: systemic erythematosus therapy - OMRIX
Alternative Names: Systemic lupus erythematosus therapy research programme - OMRIXLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator OMRIX Biopharmaceuticals
- Class Antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Systemic lupus erythematosus
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Systemic-lupus-erythematosus in Israel
- 12 Jul 2005 Preclinical trials in Systemic lupus erythematosus in Israel (unspecified route)